References
1. Simbirtsev A.S. Immunopathogenesis and prospects for immunotherapy of coronavirus infection. VICH infektsiya i immunosupressii [HIV Infection and Immunosuppression]. 2020; 12 (4): 7–22. DOI: https//doi.org/10.22328/2077-9828-2020-12-4-7-22 (in Russian)
2. Kononenko A.A., Noskov A.K., Vodyanitskaya S.Yu., Podoynitsyna O.A. Human coronaviruses capable of causing emergencies. Meditsinskiy vestnik Yuga Rossii [Medical Bulletin of the South of Russia]. 2021; 12 (1): 14–23. (in Russian)
3. Swapan K.C., Snigdha S., Maria N.M. Molecular pathogenesis, immunopathogenesis and novel therapeutic strategy against COVID-19. Front Mol Biosci. 2020; 7: 196. DOI: https//doi.org/10.3389/fmolb.2020.00196
4. Esakandari H., Nabi-Afjadi M., Fakkari-Afjadi J., Farahmandian N., Miresmaeili S.M., Bahreini. E. A comprehensive review of COVID-19 characteristics. Biol Proced Online. 2020; 22: 19. DOI: https//doi.org/10.1186/s12575-020-00128-2
5. Order «On Approval of Pharmacovigilance Procedure». 15.02.2017. No. 1071. Registered with the Ministry of Justice of Russia on March 20, 2017 No. 46039. (in Russian)
6. Hossen M.S., Barek M.A., Jahan N., Safiqul I.M. A Review on current repurposing drugs for the treatment of COVID-19: reality and challenges. SN Compr Clin Med. 2020; 2 (10): 1777–89. DOI: https//doi.org/10.1007/s42399-020-00485-9
7. Provisional Methodological Recommendations «Prevention, Diagnosis and Treatment of New Coronavirus Infection (COVID-19)». Version 16 of 18.08.22. (in Russian)
8. Beigel J.H., Tomashek K.M., Dodd L.E., Mehta A.K., Zingman B.S., Kalil A.C., et al. Remdesivir for the treatment of Covid-19 – final report. N Engl J Med. 2020; 383 (19): 1813–26. DOI: https//doi.org/10.1056/NEJMoa2007764
9. Kim K.H. COVID-19. Int Neurourol J. 2020; 24 (1): 1. DOI: https//doi.org/10.5213/inj.2020edi.001
10. Chen G.L., Li X.F., Dai X.H., Li N., Cheng M.L., Huang Z., et. al. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Microbe. 2022; 3 (3): 193–202. DOI: https//doi.org/10.1016/S2666-5247(21)00280-9
11. Paladugu S., Donato A. Remdesivir improved time to recovery in adults hospitalized with COVID-19 and lower respiratory tract involvement. Ann Intern Med. 2020; 173 (2): JC4. DOI: https//doi.org/10.7326/ACPJ202007210-005
12. Tsvetov V.M., Mirzaev K.B., Sychev D.A. Possibility and prospects of using remdesivir in patients with COVID-19. Kachestvennaya klinicheskaya praktika [Qualitative Clinical Practice]. 2020; (S4): 99–102. DOI: https//doi.org/10.37489/2588-0519-2020-S4-99-102 (in Russian)
13. Svetlitskaya O.I., Eremin S.V., Sirosh Yu.A., Sharanova O.A., Kendenkov O.I. Role of remdesivir in the treatment of patients with COVID-19-associated acute respiratory distress syndrome. Mezhdunarodniy nauchno-issledovatel’skiy zhurnal [International Scientific Research Journal]. 2022; 4 (118): 86–8. DOI: https://doi.org/10.23670/IRJ.2022.118.4.086 (in Russian)
14. Chen Y.Z, Lin M.S., Lin Y.P., Liu Y.Z., Yang C.J. Precipitating factors of bradycardia after remdesivir administration: ICU admission and cutoff value for declining heart rate. J Microbiol Immunol Infect. 2023; 23: 1684–82. DOI: https//doi.org/10.1016/j.jmii.2023.06.004
15. Manabe T., Kambayashi, D., Akatsu H., Kudo K. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2021; 21 (1): 489. DOI: https://doi.org/10.1186/s12879-021-06164-x
16. Leonova M.V. Repurposed antimicrobials and antivirals for the treatment of COVID-19: safety and side effects in real-world clinical practice (scientific review). Consilium Medicum. 2022; 24 (9): 567–73. DOI: https//doi.org/10.26442/20751753.2022.9.201763 (in Russian)
17. Shinkai M., Tsushima K., Tanaka S., Hagiwara E., Tarumoto N., Kawada I., et al. Efficacy and safety of favipiravir in moderate COVID-19 pneumonia patients without oxygen therapy: a randomized, phase III clinical trial. Infect Dis Ther. 2021; 10 (4): 2489–509. DOI: https//doi.org/ 10.1007/s40121-021-00517-4
18. Cai Q., Yang M., Liu D., Chen J., Shu D., Xia J. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing). 2020; 10: 1192–8. DOI: https//doi.org/10.1016/j.eng.2020.03.007
19. Alotaibi M., Ali A., Alatawi D.B., Alotaibi S., Alhifany A., et al. Effectiveness and safety of favipiravir compared to hydroxychloroquine for management of Covid-19: a retrospective study. Int J Gen Med. 2021; 14: 5597–606. DOI: https//doi.org/10.2147/IJGM.S329881
20. Balakin K.V., Storozhenko R.V., Yakubova E.V. Favipiravir as COVID-19 therapy. Nauchniy byulleten’ KhimRar [KhimRar Scientific Bulletin]. 2023; (1): 1–26. (in Russian)
21. Al-Muhsen S., Al-Numair N.S., Sharif-Askari N.S., Basamh R., Alyounes B., Jabaan A., et al. Favipiravir effectiveness and safety in hospitalized moderate-severe COVID-19 patients: observational prospective multicenter investigation in Saudi Arabia. Front Med. (Lausanne). 2022; 9: 826247. DOI: https//doi.org/10.3389/fmed.2022.826247
22. Doi Y., Hibino M., Hase R., Yamamoto M., Kasamatsu Y., Hirose M., et al. A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19. Antimicrob Agents Chemother. 2020; 64 (12): e01897-20. DOI: https//doi.org/10.1128/AAC.01897-20
23. Pilkington V., Pepperrell T., Hill A. A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic? J Virus Erad. 2020; 6 (2): 45–51. DOI: https//doi.org/ 10.1016/S2055-6640(20)30016-9
24. Khokhlov A.L., Rybachkova Yu.V. The use of the new oral antiviral drug molnupiravir in the treatment of COVID-19 from a safety perspective. Kachestvennaya klinicheskaya praktika [Qualitative Clinical Practice]. 2022; (3): 35–51. DOI: https//doi.org/0.37489/2588-0519-2022-3-35-51 (in Russian)
25. The Recovery Collaborative Group’s scientific Contributions. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022; 399 (10 320): 143–51. DOI: https//doi.org/10.1016/S0140-6736 (21)01825-01830
26. Piazza G., Morrow D.A. Diagnosis, management, and pathophysiology of arterial and venous thrombosis in COVID-19. JAMA. 2020; 324 (24): 2548–9. DOI: https//doi.org/10.1001/jama.2020.23422
27. Levi M., Thachil J., Iba T., Levy J.H. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020; 7 (6): 438–40. DOI: https//doi.org/10.1016/S2352-3026(20)30145-9
28. Ruzhentsova T.A., Khavkina D.A., Chukhlyaev P.V., Garbuzov A.A., Ploskireva A.A. Effect of anticoagulant therapy on the course of COVID-19 in comorbid patients. Voprosy virusologii [Problems of Virology]. 2021; 66 (1): 40–6. DOI: https//doi.org/10.36233/0507-4088-14 (in Russian)
29. Goligher E.C., Bradbury C.A., McVerry B.J., Lawler P.R., Berger J.S., Gong M.N., et al. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med. 2021; 385 (9): 777–89. DOI: https//doi.org/10.1056/NEJMoa2103417
30. Alshabeeb M.A., Alyabsi M., Aziz M.A., Abohelaika S. Pharmacogenes that demonstrate high association evidence according to CPIC, DPWG, and PharmGKB. Front Med. 2022; 9: 1–12. DOI: https://doi.org/10.3389/fmed.2022.1001876
31. Zubiaur P., Koller D., Saiz-Rodríguez M., Navares-Gómez M., Abad-Santos F. Important pharmacogenetic information for drugs prescribed during the SARS-CoV-2 infection (COVID-19). Clin Transl Sci. 2020; 13 (6): 1023–33. DOI: https//doi.org/10.1111/cts.12866
32. Timasheva Ya.R., Nasibullin T.R., Erdman V.V., Tuktarova I.A., Mustafina O.E. Pharmacogenetic variability in three Russian populations: age-related aspects. Farmakogenetika i farmakogenomika [Pharmacogenetics and Pharmacogenomics]. 2019; (2): 32–3. DOI: https://doi.org/10.24411/2588-0527-2019-10058 (in Russian)
33. Traspov A.A., Minashkin M.M., Poyarkov S.V., Komarov A.G., Shtinova I.A., Speshilov G.I., et al. RS17713054 and RS1800629 polymorphisms of LZTFL1 and TNF genes are associated with the severity of COVID-19 course. Vestnik RGMU [Bulletin of Russian State Medical University]. 2022; (6): 35–40. DOI: https//doi.org/10.24075/vrgmu.2022.065 (in Russian)
34. Fabrizio C., Termine A., Caputo V., Megalizzi D., Calvino G., Trastulli G., et al. Analysis of genetic variants associated with COVID-19 outcome highlights different distributions among populations. J Pers Med. 2022; 12 (11): 1851. DOI: https//doi.org/10.3390/jpm12111851